NCT00819585 arm group fa090cb7261d881c9be9e1815aeb6bdf [clinicaltrials_resource:NCT00819585/arm-group/fa090cb7261d881c9be9e1815aeb6bdf]
Canakinumab 200 mg [clinicaltrials_resource:1967dae3c3ed6ab44bbfb4320338b9dd]Allopurinol [clinicaltrials_resource:3b805f875a400069d64b4966a149e09b]Placebo Matching Colchicine [clinicaltrials_resource:4143aa4d415cac569f2bba6ee3362db4]Placebo Matching Canakinumab [clinicaltrials_resource:48da36f11f12a17eee7916979ef4f42b]clinicaltrials:NCT00819585
arm group [clinicaltrials_vocabulary:arm-group]
NCT00819585 arm group fa090cb7261d881c9be9e1815aeb6bdf [clinicaltrials_resource:NCT00819585/arm-group/fa090cb7261d881c9be9e1815aeb6bdf]
Bio2RDF identifier
NCT00819585/arm-group/fa090cb7261d881c9be9e1815aeb6bdf
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 090cb7261d881c9be9e1815aeb6bdf
description [clinicaltrials_vocabulary:description]
Canakinumab 200 mg s.c. once a ...... (100 mg- 300 mg) for 24 weeks.
identifier
clinicaltrials_resource:NCT00819585/arm-group/fa090cb7261d881c9be9e1815aeb6bdf
title
NCT00819585 arm group fa090cb7261d881c9be9e1815aeb6bdf
@en
type
label
NCT00819585 arm group fa090cb7 ...... 90cb7261d881c9be9e1815aeb6bdf]
@en